Package leaflet: Information for the patient

Macitentan Sandoz 10 mg, filmomhulde tabletten

macitentan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [Nationally completed name] is and what it is used for
2. What you need to know before you take [Nationally completed name]
3. How to take [Nationally completed name]
4. Possible side effects
5. How to store [Nationally completed name]
6. Contents of the pack and other information

1. What [Nationally completed name] is and what it is used for

[Nationally completed name] contains the active substance macitentan, which belongs to the class of medicines called “endothelin receptor antagonists”.

[Nationally completed name] is used for the long-term treatment of pulmonary arterial hypertension (PAH):
- in adults of WHO Functional Class (FC) II to III
- in children under 18 years and body weight of at least 40 kg with WHO Functional Class (FC) II to III.

It can be used on its own or with other medicines for PAH. PAH is high blood pressure in the blood vessels that carry blood from the heart to the lungs (the pulmonary arteries). In people with PAH, these arteries get narrower, so the heart has to work harder to pump blood through them. This causes people to feel tired, dizzy, and short of breath.

[Nationally completed name] widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure, relieves the symptoms, and improves the course of the disease.

2. What you need to know before you take [Nationally completed name]

Do not take [Nationally completed name]

- If you are allergic to macitentan, soya, peanut or any of the other ingredients of this medicine (listed in section 6).
- If you are pregnant, if you are planning to become pregnant, or if you could become pregnant because you are not using reliable birth control (contraception). See section 'Pregnancy and breastfeeding'.
- If you are breastfeeding. See section 'Pregnancy and breastfeeding'.
- If you have liver disease or if you have very high levels of liver enzymes in your blood. Talk to your doctor, who will decide whether this medicine is suitable for you.

If any of these apply to you, please tell your doctor.

Warnings and precautions

Talk to your doctor or pharmacist before taking [Nationally completed name].

You will need blood tests, as indicated by your doctor:
Your doctor will take blood test before you start treatment with [Nationally completed name] and during treatment to test:

- whether you have anaemia (a reduced number of red blood cells)
- whether your liver is working properly

If you have anaemia (a reduced number of red blood cells), you may have the following signs:

- dizziness
- fatigue/malaise/weakness
- fast heart rate, palpitations
- pallor

If you notice any of these signs, **tell your doctor**.

Signs that your liver may not be working properly include:

- feeling sick (nausea)
- vomiting
- fever
- pain in your stomach (abdomen)
- yellowing of your skin or the whites of your eyes (jaundice)
- dark-coloured urine
- itching of your skin
- unusual tiredness or exhaustion (lethargy or fatigue)
- flu-like syndrome (joint and muscle pain with fever)

If you notice any of these signs**, tell your doctor immediately.**

If you have kidney problems, talk to your doctor before using [Nationally completed name]. Macitentan may lead to more reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.

In patients with pulmonary veno-occlusive disease (obstruction of the lung veins), the use of medicines for treatment of PAH, including [Nationally completed name], may lead to pulmonary oedema. If you have signs of pulmonary oedema when using [Nationally completed name], such as a sudden, important increase in breathlessness and low oxygen, **tell your doctor immediately**. Your doctor may perform additional tests, and will determine what treatment regimen is most suitable for you.

Children and adolescents
Do not give this medicine to children below 2 years of age because efficacy and safety have not been established.

Other medicines and [Nationally completed name]
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine. [Nationally completed name] can affect other medicines.

If you take [Nationally completed name] together with other medicines including those listed below, the effects of [Nationally completed name] or the other medicines might be altered. Please talk to your doctor or pharmacist if you are taking any of the following medicines:

- rifampicin, clarithromycin, telithromycin, ciprofloxacin, erythromycin (antibiotics used to treat
- infections),
- phenytoin (a medicine used to treat seizures),
- carbamazepine (used to treat depression and epilepsy),
- St. John's Wort (an herbal preparation used to treat depression),
- ritonavir, saquinavir (used to treat HIV infections),
- nefazodone (used to treat depression),
- ketoconazole (except shampoo), fluconazole, itraconazole, miconazole, voriconazole (medicines used against fungal infections)
- amiodarone (to control the heartbeat)
- cyclosporine (used to prevent organ rejection after transplant)
- diltiazem, verapamil (to treat high blood pressure or specific heart problems)

[Nationally completed name] with food
If you are taking piperine as a dietary supplement, this may alter how the body responds to some medicinal products, including [Nationally completed name]. Please talk to your doctor or pharmacist should this be the case.

Pregnancy and breast-feeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

[Nationally completed name] may harm unborn babies conceived before, during or soon after treatment.

- If it is possible, you could become pregnant, use a reliable form of birth control (contraception) while you are taking [Nationally completed name]. Talk to your doctor about this.
- Do not take [Nationally completed name] if you are pregnant or planning to become pregnant.
- If you become pregnant or think that you may be pregnant while you are taking [Nationally completed name], or shortly after stopping [Nationally completed name] (up to 1 month), see your doctor immediately.

If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking [Nationally completed name] and regularly (once a month) while you are taking [Nationally completed name].

It is not known if macitentan is transferred to breast milk. Do not breastfeed while you are taking [Nationally completed name]. Talk to your doctor about this.

Fertility
If you are a man taking [Nationally completed name], it is possible that this medicine may lower your sperm count. Talk to your doctor if you have any questions or concerns about this.

Driving and using machines
[Nationally completed name] can cause side effects such as headaches and hypotension (listed in section 4), and the symptoms of your condition can also make you less fit to drive or use machines.

[Nationally completed name] contains lactose, lecithin from soya and sodium
[Nationally completed name] contains a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

[Nationally completed name] contains soya lecithin derived from soya. If you are allergic to soya or peanut, do not use this medicine (see section 2 'Do not take [Nationally completed name]).

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium free'.

3. How to take [Nationally completed name]

[Nationally completed name] should only be prescribed by a doctor experienced in the treatment of pulmonary arterial hypertension.

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Adults and children aged less than 18 years weighing at least 40 kg
The recommended dose of [Nationally completed name] is one 10 mg tablet, once a day. Swallow the whole tablet, with a glass of water, do not chew or break the tablet. If you are unable to swallow tablets in whole, you should use other pharmaceutical forms containing macitentan available on the market.

You can take [Nationally completed name] with or without food. It is best to take the tablet at the same time each day.

For children weighing less than 40 kg, macitentan dispersible tablets with a lower strength are available under other brand names.

If you take more [Nationally completed name] than you should
If you have taken more tablets than you have been told to take, you may experience headache, nausea, or vomiting. Ask your doctor for advice.

If you forget to take [Nationally completed name]
If you forget to take [Nationally completed name], take a dose as soon as you remember, then continue to take your tablets at the usual times. Do not take a double dose to make up for a forgotten tablet.

If you stop taking [Nationally completed name]
[Nationally completed name] is a treatment that you will need to keep on taking to control your PAH. Do not stop taking [Nationally completed name] unless you have agreed this with your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Uncommon serious side effects (may affect up to 1 in 100 people)
- Allergic reactions (swelling around the eyes, face, lips, tongue or throat, itching and/or rash)

If you notice any of these signs, tell your doctor immediately.

Very common side effects (may affect more than 1 in 10 people)
- Anaemia (low number of red blood cells) or reduced haemoglobin
- Headache
- Bronchitis (inflammation of the airways)
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Oedema (swelling), especially of the ankles and feet

Common side effects (may affect up to 1 in 10 people)
- Pharyngitis (inflammation of the throat)
- Influenza (flu)
- Urinary tract infection (bladder infection)
- Hypotension (low blood pressure)
- Nasal congestion (blocked nose)
- Elevated liver tests
- Leukopenia (decreased white blood cell counts)
- Thrombocytopenia (decreased blood platelet counts)
- Flushing (redness of the skin)

- Increased uterine bleeding

Side effects in children and adolescents
The side effects listed above may also be seen in children. Additional side effects very commonly seen in children include upper respiratory tract infection (infected nose sinuses, or throat) and gastroenteritis (inflamed stomach and gut). Rhinitis (itchy, runny, or blocked nose) was seen commonly in children.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects. not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [Nationally completed name]

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What [Nationally completed name] contains
- The active substance is macitentan. Each film-coated tablet contains 10 mg macitentan.

-The other ingredients are lactose monohydrate, cellulose microcrystaline, croscarmellose sodium, poloxamer, povidone, sodium stearyl fumarate, polyvinyl alcohol part hydrolysed, titanium dioxide, talc, soya lecithin and xanthan gum.

What [Nationally completed name] looks like and contents of the pack
[Nationally completed name] 10 mg tablets are round, biconvex, white to off-white film coated tablet, debossed with “L” on one side and “11” on other side. Approximately 5.4 mm in diameter.

[Nationally completed name] are available in blisters containing 15 or 30 film-coated tablets or perforated unit dose blisters containing 15 x 1 or 30 x 1 film-coated tablets.

Not all pack sizes may be marketed.

Houder van de vergunning voor het in de handel brengen en fabrikant

Vergunninghouder:
Sandoz B.V.
Hospitaaldreef 29
1315 RC Almere
Nederland

Fabrikant:
Salutas Pharma GmbH
Otto-von-Guericke Allee 1
39179 Barleben
Duitsland

Dit medicijn is geregistreerd in lidstaten van de Europese Economische Ruimte onder de volgende namen:

Finland	Macitentan Sandoz 10 mg tabletti kalvopäällysteinen
Oostenrijk	Macitentan Sandoz 10 mg – Filmtabletten
België	Macitentan Sandoz 10 mg filmomhulde tabletten/ Macitentan Sandoz 10 mg comprimés/ Macitentan Sandoz 10 mg Filmtabletten
Cyprus	Macitentan Sandoz
Duitsland	Macitentan - 1 A Pharma 10 mg Filmtabletten
Denemarken	Macitentan Sandoz
Griekenland	Macitentan/Sandoz
Spanje	Macitentan Sandoz 10 mg comprimidos recubiertos con película EFG
Hongarije	Macitentan Sandoz 10 mg filmtabletta
Ierland	Macitentan Rowex 10 mg film-coated tablets
Italië	Macitentan Sandoz
Malta	Macitentan Sandoz 10 mg film-coated tablets
Nederland	Macitentan Sandoz 10 mg, filmomhulde tabletten
Noorwegen	Macitentan Sandoz
Polen	Macitentan Sandoz
Portugal	Macitentano Sandoz 10 mg Comprimido revestido por película
Zweden	Macitentan Sandoz

Deze bijsluiter is voor het laatst goedgekeurd in april 2026